Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SMS Pharmaceuticals Limited ( (IN:SMSPHARMA) ) has provided an announcement.
SMS Pharmaceuticals Limited announced the successful completion of a USFDA inspection at its Vizag manufacturing facility, which specializes in large-volume API production. The inspection concluded with one minor procedural observation, not related to data integrity, and the company will respond to the USFDA within the required timeframe. This achievement underscores SMS Pharma’s commitment to quality and compliance, reinforcing its position as a reliable partner in the global pharmaceutical industry and ensuring continued high-quality API supply to international markets.
More about SMS Pharmaceuticals Limited
Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, SMS Pharmaceuticals has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 75 countries.
Average Trading Volume: 44,909
Technical Sentiment Signal: Strong Buy
Current Market Cap: 28.98B INR
See more data about SMSPHARMA stock on TipRanks’ Stock Analysis page.